Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APOL1 | O14791 | 4/20 | 0.51 |
| ▸ | TACR1 | P25103 | 1/20 | 0.50 |
| ▸ | PPARG | P37231 | 5/20 | 0.46 |
| ▸ | CXCR2 | P25025 | 3/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24099470 | 1.00 | APOL1 (0.51) | APOL1TACR1PPARGCXCR2 | |
| SCHEMBL24907079 | 0.94 | APOL1 (0.57) | APOL1PPARGCXCR2 | |
| SCHEMBL24099388 | 0.94 | APOL1 (0.57) | APOL1PPARGCXCR2 | |
| SCHEMBL24098993 | 0.86 | APOL1 (0.55) | APOL1TACR1PPARGCXCR2 | |
| SCHEMBL24098889 | 0.86 | APOL1 (0.55) | APOL1TACR1PPARGCXCR2 | |
| SCHEMBL24098988 | 0.86 | APOL1 (0.55) | APOL1TACR1PPARGCXCR2 | |
| SCHEMBL24098887 | 0.83 | APOL1 (0.59) | APOL1PPARGCXCR2 | |
| SCHEMBL24099481 | 0.82 | APOL1 (0.56) | APOL1TACR1PPARGCXCR2 | |
| SCHEMBL24099201 | 0.82 | TACR1 (0.55) | APOL1TACR1PPARGCXCR2 | |
| SCHEMBL6929600 | 0.81 | PPARG (0.66) | APOL1TACR1PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115867532-A | Inhibitors of APOL1 and uses thereof | 弗特克斯药品有限公司 | 2023-03-28 | — | — | CN | disclosed |
| US-20230014907-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED | 2023-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230014907-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | APOL1, APOB, NPC1L1 | APOL1 1/4885TACR1 3857/4885PPARG 2747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.